Mina Makar

I hold the role of Senior Vice President of Global Cardiovascular, Renal and Metabolism (CVRM) in the BioPharmaceuticals Business Unit at AstraZeneca. In this pivotal role, I address unmet needs across four interconnected disease areas: heart failure, cardiovascular disease, renal diseases and metabolic diseases. My efforts are instrumental in driving AstraZeneca's ambition to slow or stop progression and hopefully one day even cure these progressive, and often devastating diseases by maximising the company's medicines, delivering innovative solutions, and advancing the pipeline. 

With a career in healthcare spanning three decades, I began my journey as a pharmacist. Throughout my professional life, I have been dedicated to bringing important medicines to people with limited or no treatment options. I bring to the CVRM team extensive experience in marketing and sales, payer and access strategies, as well as leadership and engagement. 

My tenure with AstraZeneca extends over two decades, during which I have assumed roles of increasing responsibility across multiple therapy areas within the organisation. Prior to my current position, I served as the Senior Vice President of US Respiratory & Immunology. In this role, I led significant growth and expansion of the therapy area, overseeing several new product launches, including AstraZeneca's first respiratory biologic. Additionally, I spearheaded the delivery of innovative approaches in digital health and patient-centric support programs. 

Recognising the deep commitment AstraZeneca has in the CVRM therapy area, I am poised to lead the company into the future of CVRM care, focusing on improving outcomes for millions of people globally living with these conditions.